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Abstract
Background. Phosphate binders are required to control se-
rum phosphorus in dialysis patients. A phosphate binder
combining calcium and magnesium offers an interesting
therapeutic option.
Methods. This controlled randomized, investigator-
masked, multicentre trial investigated the effect of calci-
um acetate/magnesium carbonate (CaMg) on serum
phosphorus levels compared with sevelamer hydrochloride
(HCl). The study aim was to show non-inferiority of CaMg
in lowering serum phosphorus levels into Kidney Disease
Outcome Quality Initiative (K/DOQI) target level range
after 24 weeks. Three hundred and twenty-six patients
from five European countries were included. After a
phosphate binder washout period, 255 patients were ran-
domized in a 1:1 fashion. Two hundred and four patients
completedthestudy per protocol(CaMg, N=105;dropouts
N = 18; sevelamer-HCl, N = 99; dropouts N = 34). Patient
baseline characteristics were similar in both groups.
Results. Serum phosphorus levels had decreased signifi-
cantly with both drugs at week 25, and the study hypothesis
of CaMg not being inferior to sevelamer-HCl was con-
firmed. The area under the curve for serum phosphorus
(P = 0.0042) and the number of visits above K/DOQI
(≤1.78 mmol/L, P = 0.0198) and Kidney disease: Improv-
ing global outcomes (KDIGO) targets (≤1.45 mmol/L,
P = 0.0067) were significantly lower with CaMg. Ionized
serum calcium did not differ between groups; total serum
calcium increased in the CaMg group (treatment difference
0.0477mmol/L;P=0.0032)but was not associated with a
higher risk of hypercalcaemia. An asymptomatic increase
in serum magnesium occurred in CaMg-treated patients
(treatment difference 0.2597 mmol/L, P < 0.0001). There
was no difference in the number of patients with adverse
events.
Conclusion. CaMg was non-inferior to the comparator
at controlling serum phosphorus levels at Week 25.
There was no change in ionized calcium; there was
minimal increase in total serum calcium and a small in-
crease in serum magnesium. It had a good tolerability
profile and thus may represent an effective treatment
of hyperphosphataemia.
Keywords: calcium acetate; haemodialysis; magnesium carbonate;
phosphate binder; safety parameters
Introduction
In patients with chronic kidney disease stage 5 (CKD 5),
increasing evidence links inadequate serum phosphorus
control to higher morbidity and mortality [1–6]. As a
consequence, serum phosphorus lowering appears to be
a key therapeutic goal. In addition to optimal dialysis
treatment and dietary restrictions, oral phosphate binders
are the treatment of choice in patients with hyperpho-
sphataemia [7].
Calcium acetate/magnesium carbonate (CaMg) is a
combination phosphate binder. Both components separate-
ly or magnesium carbonate together with calcium carbon-
ate are already well-established phosphate-lowering agents
[8–18]. As high doses of phosphate binders are often re-
quired to achieve sufficient phosphate reduction, the risk
of hypercalcaemia must be considered when using a pure
calcium salt as a phosphate binder. Calcium–magnesium
combined preparations are effective alternatives because
the proportion of calcium is reduced compared with drugs
containing calcium salts only, limiting the risk of hypercal-
caemia and of a continuously positivecalcium balance [19].
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combined preparation is that increased serum magnesium
levels have been associated in dialysis patients with ben-
eficial effects such as reduced vascular calcification and
improved survival [20–25]. However, only one prospec-
tive study, in which intima media thickness was investi-
gated in a small number of patients, provides indirect
supporting evidence for reduced vascular calcification
[26] with magnesium supplementation.
A phosphate binder combining a reduced calcium expo-
sure and the possible beneficial effect of controlled mag-
nesium administration, potentially offering the double
advantage of favourable gastrointestinal tolerance and pos-
itive cardiovascular effects, seemed worthwhile to investi-
gate for its phosphorus-lowering capacity in comparison
with a well-established drug in a large-scale controlled ran-
domized study for the first time.
Materials and methods
Study population
Patients aged 18–85 years, stable, without serious illness, on 4–6h
haemodialysis (HD) or online haemodiafiltration (HDF) 3× per week
for at least 3 months were enrolled in this study. The main eligibility
criteria were not taking any magnesium- or calcium-containing supple-
ment, serum phosphorus ≥1.78 mmol/L (≥5.5 mg/dL), serum calcium
≤2.6 mmol/L (≤10.4 mg/dL) and serum magnesium ≤1.5 mmol/L
(≤3.65 mg/dL) after washout of phosphate binders (detailed inclusion
and exclusion criteria are provided in Supplementary Table 1). Thirty-
six dialysis centres in five countries (Germany, Poland, Portugal, Romania
and Spain) participated in this study. The study was conducted in confor-
mity with International Conference on Harmonisation - Good Clinical
Practice (ICH-GCP) and the Declaration of Helsinki. The protocol and
informed consent form were approved by the responsible Ethics Com-
mittees. The study was registered at the European clinical trial database:
EudraCT No.: 2006-002589-20.
Study procedure and study design
This prospective, controlled, randomized, multicentre, investigator-
masked, parallel-group study compared tolerability and efficacy of two
different oral phosphate binder treatments (CaMg and sevelamer-HCl)
for 24 weeks in HD or online HDF patients. The primary endpoint of this
trial was the exploration of the efficacy of CaMg compared with sevela-
mer-HCl as an active control. The primary target variable was serum
phosphorus at Week 25. After a washout/run-in phase of 2 to 3 weeks,
during which all phosphate binders had to be discontinued and all patients
were switched to the study dialysis fluid composition (dialysate calcium
of 1.5 or 1.25 mmol/L, dependent on prior prescription, and dialysate
magnesium of 0.5 mmol/L) for at least 2 weeks, patients were randomized
in a 1:1 ratio (Figure 1A). Randomization was central via Fax and strat-
ified according to the dialysis mode (HD vs online HDF). The dialysate
calcium composition was constant throughout the study at either 1.25 or
1.5 mmol/L. Only those patients being treated with a dialysate of
1.25 mmol/L during the study could be switched to a dialysate of
1.5 mmol/L in the event of hypocalcaemia.
Study medication
Patients received one of the two study medications: calcium acetate
435 mg containing 110 mg elemental calcium combined with magnesium
carbonate 235 mg containing 60 mg elemental magnesium (OsvaRen
®)o r
sevelamer-HCl 800 mg (Renagel
®) for 24 weeks. Blinding of the study
medication was virtually impossible, so that an ‘investigator-masked’ ap-
proach was chosen: the trial medication was packed in opaque blister
strips and only administered by the study nurse whereby the investigator
and other site staff was masked to trial medication. Furthermore, the pri-
mary efficacy parameter (serum phosphorus) was determined in a central
laboratory blinded to treatment allocation as were all other persons in-
volved in the trial.
Patient compliance with the treatment was checked weekly from pa-
tients’ diary entries, by counting of used and unused tablets and by the
on-site study monitor dispensing cards. Starting dose of study drugs
was at least four tablets per day. Thereafter, following each laboratory
result and depending on individual dietary intake, the dose was increased
by one to three tablets per day (i.e. one to two tablets per meal) in order to
reduce serum phosphorus levels below 1.78 mmol/L (5.5 mg/dL) in the
absence of hypercalcaemia or hypermagnesaemia. The number of tablets
was prescribed on an individual basis according to the estimated phos-
phate content of each meal. Regular dietary advice took place prior to
the start of and throughout the study.
Study parameters
The primary efficacy parameter was serum phosphorus at Week 25. Sec-
ondary efficacy parameters were serum calcium and magnesium at Week
25; further efficacy parameters were number of visits with serum phos-
phorus ≤1.78 mmol/L (≤5.5 mg/dL) and ≤1.45 mmol/L (≤4.49 mg/dL),
serum calcium level within the Kidney Disease Outcome Quality Initia-
tive (K/DOQI) recommendation of 2.10 to 2.37 mmol/L (8.41–9.50 mg/
dL) and number of visits with a serum calcium and magnesium above
[upper limit of normal (ULN)] and below [lower limit of normal
(LLN)] the normal range, as well as their respective area under the curve
(AUC). Other parameters measured included intact parathormone (iPTH),
actual bicarbonate, base excess, low-density lipoprotein (LDL)-cholester-
ol and potassium. Study medication intake (number of ingested tablets per
day) was recorded. Ten visits took place at weekly (until Week 5), fort-
nightly (Weeks 5–9) and four-weekly intervals (Weeks 9–25).
Tolerability was assessed by means of adverse event profile [ad-
verse event (AE); serious adverse event (SAE)], safety laboratory para-
meters, electrocardiogram (ECG) and vital signs. Blood gas analyser
measurements were taken at the bedside; screening values of serum
P, Ca, Mg and iPTH were assessed at the local laboratories of the trial
centres. All other laboratory parameter measurements were performed
at the central laboratory. A Gastrointestinal Quality of Life Index
(GIQLI) validated for gastrointestinal disease [27] was evaluated five
times during the study.
Statistical analysis
The following non-inferiority hypothesis was tested: H0: serum phospho-
rus level under CaMg is more than 0.15 mmol/L (0.46 mg/dL) higher than
serum phosphorus level under sevelamer-HCl vs H1: serum phosphorus
level under CaMg is up to 0.15 mmol/L higher, equal or lower than serum
phosphorus level under sevelamer-HCl (a Δ of 0.15 mmol/L assumes no
clinical difference [28]).
This hypothesis was tested using the principle of ‘confidence interval
inclusion’. The one-sided 97.5% confidence interval was calculated using
an analysis of covariance model including factors for study treatment,
centre (pooled), baseline values, dialysate calcium concentration and
use of vitamin D and of cinacalcet as covariates as these factors may have
a significant influence on the final results.
As the sample size in each treatment group was 100 (a total sample
size of 200), a two-group one-sided t-test at a 2.5% significance level
had 80% power to reject the null hypothesis that the difference in means
of serum phosphorus between CaMg and sevelamer-HCl at Week 25 is
>0.15 mmol/L. This was based on the assumptions that the expected dif-
ference in means is −0.05 mmol/L and the common standard deviation is
0.5 mmol/L, as in previous research reports. To allow for a dropout rate of
about 20% for the per-protocol analysis, a total sample size of 248 pa-
tients was suggested.
Response rates were tested using a logistic regression model. The
number of visits was tested using Wilcoxon rank-sum tests. All other sec-
ondary and further efficacy endpoints were tested using the same analysis
of covariance (ANCOVA) model as for the primary endpoint. Baseline
characteristics were tested using t-tests or chi-square tests depending on
the distribution of the data. These tests were carried out at a two-sided
significance level α of 5%.
The main population for the confirmative analysis of the primary effi-
cacy variablewas the per-protocol set (PPS), i.e. all patients whowere ran-
domized and completed the study per protocol. All analyses of secondary
3708 A.L.M. de Francisco et al.Fig. 1. (A) Study design and procedure. (B) CONSORT diagram demonstrating patient flow including analysis sets.
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using the Last Observation Carried Forward (LOCF) method. The FAS
consisted of all patients who were randomized, took study medication
and had at least one subsequent efficacy evaluation. The safety parameter
evaluation was performed on the safety population (SAS), which consisted
of all randomized patients who took study medication. Data are presented
as means ± SD, figures are presented as means ± SEMs. For differences
between groups, the least square means, i.e. the differences within-group
means, appropriately adjusted for the other factors in the model, are given.
As for all evaluations, the factors pooled centre and baseline value were
significant, only the ones in addition to these are mentioned in the Results
section.
Results
Patients and baseline characteristics
The first patient entered the study on 26 November 2007,
and the last patient completed the study on 25 March 2009.
Three hundred and twenty-six haemodialysis patients were
enrolled in order to reach the number of patients described
above. Seventy-one patients were failures during washout/
run-in, the majority due to unexpectedly low serum phos-
phorus levels measured between screening and the third
week of washout (N = 45). Finally, 255 patients were ran-
domized, and 204 patients completed the study per proto-
col (CaMg, N = 105; sevelamer-HCl, N = 99, see
Figure 1B, CONSORT diagram [29]).
The most frequent reasons for dropout after randomiza-
tion were withdrawal of informed consent (CaMg: N =9 ,
sevelamer-HCl: N = 19) and adverse events (CaMg: N =4 ,
sevelamer-HCl: N = 9) (Figure 1B).
Baseline demographics, screening laboratory parameters
and baseline covariates of the study patients are shown in
Table 1. There were no statistically significant differences
in any of the parameters between the two groups. There
were also no differences between groups with regards to
co-morbidities, including diabetes mellitus (24.8% in the
CaMg group vs 20.2% in the sevelamer-HCl group, P =
0.4360) and the use of prior and concomitant medications
including vitamin D and calcimimetics. The percentage of
patients receiving any form of vitamin D was higher at
baseline in the CaMg group (CaMg: 38.1%; sevelamer-
HCl: 29.3%) and did not change significantly in either
group. Also, the use of calcimimetics did not change over
time.
The mean percentage compliance with study medica-
tion intake was close to 100% in both groups. Average
daily study medication intake was slightly but signifi-
Table 1. Patients’demographics, baseline characteristics (PPS, N = 204), screening laboratory values and covariate disposition at baseline (data given as
mean ± SD, N or %)
Parameter
CaMg Sevelamer-HCl
P-value (N = 105) (N = 99)
Age (years) 59.2 ± 13.72 55.9 ± 11.75 0.0641
Gender N (%)
Female 49 (46.7) 48 (48.5) 0.6554
Male 56 (53.3) 51 (51.5)
Weight (kg) 73.8 ± 13.7 74.9 ± 12.4 0.5419
Height (cm) 165.4 ± 8.1 166.9 ± 8.8 0.1980
BMI (kg/m
2) 27.0 ± 4.6 27.0 ± 3.8 0.8857
Dialysis vintage (years) 4.9 ± 3.9 5.1 ± 4.2 0.6777
Primary diagnosis N (%)
a
Primary chronic glomerulonephritis N (%) 21 (20.0) 24 (24.2) 0.4652
Pyelonephritis/interstitial nephritis N (%) 20 (19.0) 15 (15.2) 0.4607
Hypertensive nephropathy/vascular disease N (%) 12 (11.4) 11 (11.1) 0.9429
Secondary glomerulonephritis/systemic diseases,
including diabetes N (%)
16 (15.2) 19 (19.2) 0.4541
Familiar/hereditary renal diseases N (%) 11 (10.5) 16 (16.2) 0.2311
Aetiology unknown N (%) 20 (19.0) 11 (11.1) 0.1145
Other N (%) 6 (5.7) 7 (7.1) 0.6918
Screening laboratory parameters
Serum phosphorus N (mmol/L) 2.10 ± 0.54 2.10 ± 0.59 0.9246
Total serum calcium N (mmol/L) 2.14 ± 0.25 2.18 ± 0.21 0.3226
Serum magnesium N (mmol/L) 1.20 ± 0.29 1.23 ± 0.28 0.5236
Serum iPTH N (pg/mL) 382.90 ± 199.07 338.18 ± 180.09 0.0946
Kt/V 1.5 ± 0.24 1.5 ± 0.22 0.4871
Disposition of covariates at baseline N (%)
Vitamin D3 (any form) 40 (38.1) 29 (29.3) 0.1841
Calcimimetics 9 (8.6) 9 (9.1) 0.8960
Dialysis type
Haemodialysis 97 (92.4) 85 (85.6)
Online HDF 8 (7.6) 14 (14.4) 0.1334
Dialysis fluid type (Calcium)
other 2 (1.9) 1 (1.01)
1.25 mmol/L 41 (39.1) 30 (30.3)
1.50 mmol/L 62 (59.1) 68 (68.7) 0.3430
aMore than one answer could be given.
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(CaMg: 7.3 ± 3.03; sevelamer-HCl: 8.1 ± 2.87 tablets/
day; P = 0.0420) (Figure 2A).
Primary efficacy endpoint serum phosphorus
With both study treatments, significant reductions in se-
rum phosphorus were achieved. The mean reduction at
Week 25 was not different between the CaMg group
(−0.761 ± 0.5805 mmol/L; −2.356 ± 1.7972 mg/dL)
and the sevelamer-HCl group (−0.711 ± 0.5850 mmol/L;
−2.201 ± 0.8111 mg/dL). Serumphosphorus levelachieved
after 25 weeks was 1.704 ± 0.4806 mmol/L (5.276 ±
1.4879 mg/dL) in the CaMg group in comparison with
1.769 ± 0.6066 mmol/L (5.477 ± 1.8780 mg/dL) in the
sevelamer-HCl group (Figure 2B; Table 2) with a treat-
ment difference of −0.0693 mmol/L (−0.2146 mg/dL). The
corresponding one-sided 97.5% confidence interval
was [−∞, 0.0692 mmol/L; 0.2142 mg/dL]. As the
non-inferiority margin of 0.15 mmol/L was not part of this
confidence interval, the non-inferiorityof CaMg against se-
velamer-HCl was statistically proven (Table 2).
Further phosphorus-related efficacy parameters
The AUC of serum phosphorus was significantly lower
in the CaMg group compared with the sevelamer-HCl
group with a difference of −24.5264 mmol/L × days
(−75.9331 mg/dL × days), (P = 0.0042). Furthermore,
the number of visits when target serum phosphorus levels
(≤1.78 mmol/L; 5.51 mg/dL and ≤1.45 mmol/L; 4.49 mg/
dL) were reached and the time to reach these targets were
significantly higher and shorter in the CaMg group in
comparison with the sevelamer-HCl group (Table 2).
Calcium-related efficacy parameters
No significant differences for ionized serum calcium were
seen between the groups (Table 3; Figure 3A). During the
course of the study, total serum calcium increased signifi-
cantly in the CaMg group, while no changes were observed
in the sevelamer-HCl group (Table 3; Figure 3B). The treat-
ment difference was 0.0477 mmol/L (0.1913 mg/dL)
(P = 0.0032).
Fig. 2. (A) Study medication intake per day and group over time in
the CaMg group (n = 101) and the Sevelamer-HCl group (n = 90)
(PPS); P = 0.0420 (ANOVA). (B) Time course of serum phosphorus
over 24 weeks for the CaMg group (n = 105); and the sevelamer-HCl
group (n = 99) (PPS).
Table 2. Serum phosphorus: values at baseline and at week 25, changes from baseline, area under the curve (AUC) until Week 25, number of visits
where target serum phosphorus (sP) was reached and time to reach target values
Parameter
CaMg Sevelamer-HCl
P-value N (Mean ± SD) N (Mean ± SD)
Serum phosphorus (mmol/L)
a
Baseline 105 2.464 ± 0.4930 99 2.480 ± 0.4704 na
c
Week 25 105 1.704 ± 0.4806 1.769 ± 0.6066 na
c
Change at Week 25 105 −0.761 ± 0.5805 99 −0.711 ± 0.5850 na
c
Treatment difference (LS-means) [confidence interval] −0.0693 [-∞, 0.0692]
AUC of serum phosphorus (mmol/L × days)
b 122 298.935 ± 72.0315 122 323.914 ± 81.2415
Treatment difference (LS-means) [confidence interval] −24.5264 [−41.1978, −7.8550] 0.0042
No. of visits (N) target sP (≤ 1.78 mmol/L) reached
b 122 4.91 ± 3.275 122 3.96 ± 3.363 0.0198
No. of visits (N) target sP (≤ 1.45 mmol/L) reached
b 122 2.65 ± 2.784 122 1.81 ± 2.420 0.0067
Time (days) to target sP (≤ 1.78 mmol/L)
b 122 16 122 30 0.0018
Time (days) to target sP (≤ 1.45 mmol/L)
b 122 57 122 140 0.0052
a(PPS, N = 204).
b(FAS, N = 244).
cNot applicable.
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cium between 2.10 and 2.37 mmol/L; 8.41 and 9.50 mg/
dL) [30] were also not different between CaMg and Seve-
lamer-HCl, i.e. 65.6% vs 60.7%, respectively (P = 0.3158).
The number of visits of serum Ca > ULN (>2.6 mmol/L;
>10.42 mg/dL) and serum Ca < LLN (<2.2 mmol/L;
<8.82 mg/dL), as well as above and below the K/DOQI
ranges, which are summarized in Table 3, also did not dif-
fer. All total serum calcium-related evaluations have been
repeated with albumin corrected total serum calcium, con-
firming the above-mentioned results (data not shown).
Magnesium-related efficacy parameters
Serummagnesiumvaluesatbaselineandchangesfrombase-
line, number of episodes of Mg > ULN (>1.05 mmol/L;
2.55 mg/dL) and of Mg < LLN (<0.65 mmol/L;
1.58 mg/dL) after 24 weeks of treatment are summarized
inTable3.Duringthecourseofthestudy,serummagnesium
increased significantly in the CaMg group, while only a
slight increase in the sevelamer-HCl group was observed
(Figure 4). The treatment difference was 0.2597 mmol/L
(0.6313 mg/dL) (P < 0.0001). The number of episodes of
Mg > ULN were higher in the CaMg group compared with
the sevelamer-HCl group. In both treatment groups, nearly
no episodes of Mg < LLN (0.04 ± 0.237 for both groups)
occurred during the course of the study.
iPTH and alkaline phosphatase
iPTH decreased during the course of the study in both
groups until Week 9 and then increased significantly in
the sevelamer-HCl group but without any further signifi-
cant change in the CaMg group (Table 4, Figure 5). At
Week 25, the treatment difference was −64.4773 pg/mL
which was statistically significant (P = 0.0085). The
AUC of iPTH was also significantly lower in the CaMg
group (data not shown). Alkaline phosphatase (AP) in-
creased significantly in both groups until Week 9 (P <
0.0001 for both groups). Thereafter, AP increased like
iPTH in the sevelamer-HCl group but not in the CaMg
group. At Week 25, the treatment difference was statisti-
cally significantly different (P < 0.0001) with the respec-
tive mean difference of −24.0067 U/L (Table 4).
Other biochemical parameters
Values of other biochemical parameters are summarized in
Table 5. After 25 weeks, a significant difference in actual
bicarbonate and base excess was noted between groups. In
addition, LDL-cholesterol decreased significantly in the
sevelamer-HCl group. No change was observed in the
CaMg group. Neither high-density lipoprotein-cholesterol
nor triglycerides showed any significant change within
groups or difference between groups (data not shown). Se-
rum potassium increased in the CaMg group and stayed
almost the same in the sevelamer-HCl group.
Gastrointestinal quality of life index
The GIQLI did not change over time and was not different
between groups.
Safety parameters
Adverse events. The number of patients with AEs and
SAEs were comparable in both treatment groups. There
was no difference regarding occurrence of any AEs be-
tween groups. In the CaMg group, fewer patients experi-
Table 3. Serum calcium and magnesium baseline values, changes from baseline values at Week 25 and number of visits > ULN and <LLN, as well as
above and below K/DOQI range (for Ca) (FAS, N = 244)
Parameter
CaMg Sevelamer-HCl
P-value N (Mean ± SD) N (Mean ± SD)
Ionized calcium (mmol/L)
Baseline 113 1.071 ± 0.1608 112 1.076 ± 0.1306
Week 25 120 1.104 ± 0.1210 119 1.113 ± 0.1063
Change at Week 25 112 0.036 ± 0.1702 110 0.036 ± 0.1369
Treatment difference (LS-means) [confidence interval] −0.0015 [−0.0294, 0.0264] 0.9173
Total serum calcium (mmol/L)
Baseline 122 2.148 ± 0.2288 122 2.185 ± 0.1820
Week 25 122 2.219 ± 0.1565 122 2.189 ± 0.1574
Change at Week 25 122 0.071 ± 0.1790 122 0.004 ± 0.1522
Treatment difference (LS-means) [confidence interval] 0.0477 [0.0162, 0.0793] 0.0032
No. of visits Ca > ULN (2.6 mmol/L) 122 0.11 ± 0.460 122 0.07 ± 0.563 0.2374
No. of visits Ca < LLN (2.2 mmol/L) 122 4.31 ± 3.695 122 4.55 ± 3.827 0.6839
No. of visits Ca > K/DOQI range (2.37 mmol/L) 122 1.81 ± 2.881 122 1.25 ± 2.412 0.1005
No. of visits Ca < K/DOQI range (2.10 mmol/L) 122 2.23 ± 2.911 122 2.38 ± 3.178 0.4809
Serum magnesium (mmol/L)
Baseline 122 0.993 ± 0.1544 122 0.996 ± 0.1613
Week 25 122 1.297 ± 0.2547 122 1.039 ± 0.1851
Change at Week 25 122 0.304 ± 0.2285 122 0.043 ± 0.1453
Treatment difference (LS-means) [confidence interval] 0.2597 [0.2137, 0.3056] <0.0001
No. of visits Mg > ULN (1.05 mmol/L) 122 7.86 ± 2.514 122 4.10 ± 3.797 <0.0001
No. of visits Mg < LLN (0.65 mmol/L) 122 0.04 ± 0.237 122 0.04 ± 0.237 1.0000
3712 A.L.M. de Francisco et al.enced AEs leading to study withdrawal (Figure 1B). The
intensity of about 80% of AEs was classified as mild. A
total of 16.1% AEs in the CaMg group and 19.7% in
sevelamer-HCl-treated patients were classified as moder-
ate; 4.0% and 2.5% of AEs, respectively, were judged to
be severe. None of the SAEs was judged to be related;
their number was slightly lower in the CaMg group. Re-
lated gastrointestinal AEs were more frequently noted in
the sevelamer-HCl group (23.6% of subjects vs 13.6%
in the CaMg group). Related ‘metabolism disorders’,
such as electrolyte disturbances, were more frequent in
the CaMg group, most of them were episodes of asymp-
tomatic hypermagnesaemia reported as related AE by the
treating physician (8.8% vs 2.4% in the sevelamer-HCl
group). In none of the other AEs was there any differ-
ence between groups, particularly in relation to cardiac
dysrhythmia, muscle spasm or cramps.
Other haematology, biochemistry parameters, vital signs.
Mean ± SD values of haematology, bedside laboratory,
Kt/V and serum chemistry parameters fluctuated within
expected normal variation in both treatment groups.
The same applied to vital signs and ECG.
Discussion
The main purpose of this study was to determine whether
treatment of hyperphosphataemia could be achieved effi-
ciently with a phosphate binder combining calcium and
magnesium salts in comparison with a well-established
non-calcium-containing phosphate binder. Confirming
the study hypothesis, serum phosphorus levels at Week
25 were at least as efficiently lowered with the use of
CaMg as with sevelamer-HCl. Furthermore, when serum
phosphorus control over time was evaluated, it was signif-
icantly lower in the group assigned to the CaMg phosphate
binder (P = 0.0042). In addition, both predefined target
ranges of serum phosphorus (≤1.78 mmol/L; 5.51 mg/
dL and ≤1.45 mmol/L; 4.49 mg/dL) were significantly
more often reached with CaMg (P = 0.0198 and P =
0.0067, respectively). Furthermore, the time to target
was shorter with CaMg; as an example, the time needed
for 50% of patients to achieve a target of serum phospho-
rus ≤1.45 mmol/L was reduced by 84 days. Taken togeth-
er, these results suggest that the control of serum
phosphorus levels could be attained more easily with
CaMg. The number of tablets needed to achieve these re-
sults was slightly lower in the CaMg group and overall
comparable or lower than in other studies using calcium
salts [9,10,12]. Also, the described phosphate-lowering ef-
fect in this study is comparable with [10,31] or superior to
[9,10,32] other studies, in which pure calcium salts were
investigated in comparison with sevelamer-HCl. This is
in line with recent systematic reviews [33,34]. However,
in general it is a challenge to control serum phosphorus
adequately [5].
Sevelamerwaschosenasacomparatorbecauseoneofthe
discussed advantages of sevelamer use is its lack of produc-
ing a positive calcium burden, an observation that was re-
peatedly linked to a decreased rate of calcification [31,35–
38].Inthisstudy withacalciumandmagnesium-containing
phosphate binder, we did not find any difference in ionized
serum calcium levels, a small, albeit statistically significant
difference in total serum calcium of 0.0477 mmol/L
(0.1908mg/dL)andveryfew,lessthanone,hypercalcaemic
episodes with no difference between groups. In contrast, in
studieswherepurecalciumsaltswereadministered,aserum
Fig. 3. (A) Time course of ionized serum calcium of the CaMg group
(n = 120) and of the sevelamer-HCl group (n = 119) (FAS); P = 0.9173
(ANCOVA). (B) Time course of total serum calcium of the CaMg group
(n = 122) and of the sevelamer-HCl group (n = 122) (FAS); P = 0.0032
(ANCOVA).
Fig. 4. Time course of serum magnesium of the CaMg group (n = 122)
and of the sevelamer-HCl group (n = 122) (FAS); P <0.0001 (ANCOVA).
Calcium acetate/magnesium carbonate (CaMg) in HD patients 3713calcium increase of up to 0.15 mmol/L (0.6 mg/dL) was ob-
served [9,10,31,32]. The number of hypercalcaemic epi-
sodes was also much more pronounced in other studies
[10,31,35,37,39]. These results may indicate a clinically
meaningful reduction in calcium burden, as the daily ele-
mental calcium applied in this study was only between
25% and 50% of other studies with pure calcium salts
[10,12,15,40]. Nevertheless, it was beyond the scope of this
studytoassesscalcium balance,andspecifictrialswouldbe
needed to address this question.
Magnesium-based phosphate binders have been used in
the past with excellent results [14–16,24]. However, there
always has been some apprehension related to the potential
negative consequences of a rise in serum magnesium. The
observed increase in serum magnesium in the CaMg group
wasexpectedbasedonpastexperience[19]andcomparable
with other studies [15,41–44]. In our study, a plateau was
r e a c h e da ta r o u n d7 –9 weeks, which was not associated
with any clinical side effects, especially not with an appar-
ent increased frequency of diarrhoea. An elevation of se-
rum magnesium levels is common in patients on
haemodialysis [21,25,45,46], even when not treated with
a magnesium-containing phosphate binder. Serum magne-
sium levels are largely dependent on dialysis fluid concen-
tration as the only possibility to eliminate magnesium is via
dialysis once residual renal function has disappeared [46–
48]. In our study population, mean serum magnesium level
was already elevated at screening (Table 1). More than
40% of patients had been treated with a dialysis fluid mag-
nesium concentration of 1.00 mmol/L (2.43 mg/dL); their
mean serum magnesium concentration was 1.34 mmol/L,
which was considerably higher than the mean Mg concen-
trations at Week 25 in the CaMg group. Therefore, the gen-
eral recommendation to use a dialysis fluid with a Mg
concentration of 0.5 mmol/L or lower, independent of the
phosphate binder used, might be considered. However, the
optimal dialysate Mg concentration can only be established
by specifically designed studies. Magnesium has been de-
scribed as having a much wider therapeutic range than cal-
cium, and as such hypermagnesaemia at levels up to
1.5 mmol/L (3.65 mg/dL) is not associated with clinical
effects [14,43]. Neuromuscular side effects may only
become apparent at levels of 2 to 3 mmol/L (4.86 to
7.29 mg/dL) [23].
There is concern that increased serum magnesium levels
may have an effect on bone in dialysis patients dependent
on its PTH-lowering effect as well as independently of it
(discussed in [23]). It was not the aim of this study to in-
vestigate bone histology, but identifying the role of mag-
nesium in the development of bone mineral disorders
remains an important open question.
On the other hand, it is also important to emphasize
the other ‘face of the coin’: magnesium is a potent inhib-
itor of the calcification process, as has been shown in vi-
tro [49] and in experimental animal studies which
demonstrated that experimental magnesium deficiency
is related to the development of dystrophic calcifications
[50]. In addition, also in CKD 5 and the general popula-
tion, mildly elevated magnesium levels have been associ-
Table 4. Serum iPTH and alkaline phosphatase: values at baseline, week 9 and 25 and changes from baseline (FAS, N = 244)
Parameter
CaMg Sevelamer-HCl
P-value N (Mean ± SD) N (Mean ± SD)
Serum iPTH (pg/mL)
Baseline 119 450.84 ± 273.494 118 438.97 ± 238.112
Week 9 118 361.25 ± 278.526 112 357.71 ± 201.909
Change at Week 9 115 −85.28 ± 195.308 108 −72.69 ± 154.429 0.6059
Week 25 118 337.20 ± 266.357 112 384.67 ± 226.349
Change at Week 25 115 −109.24 ± 229.903 108 −43.98 ± 171.438
Treatment difference (LS-means) [confidence interval] −64.4773 [−112.3087, −16.6459] 0.0085
Significant covariate factor
Intake of calcimimetics 0.0211
Serum alkaline phosphatase (U/L)
Baseline 122 100.39 ± 49.689 122 93.00 ± 38.384
Week 9 116 108.44 ± 52.237 104 120.42 ± 52.675
Change at Week 9 116 8.85 ± 23.523 104 25.32 ± 27.006 <0.0001
Week 25 116 106.84 ± 53.803 105 125.93 ± 53.479
Change at Week 25 116 7.26 ± 32.438 105 30.90 ± 34.101
Treatment difference (LS-means) [confidence interval] −24.0067 [−32.8963, −15.1175] <0.0001
Fig. 5. Time course of iPTH of the CaMg group (n = 118) and of the
sevelamer-HCl group (n = 112) (FAS), P = 0.0085 (ANCOVA); within-
group changes CaMg: *Week 9 vs baseline: P < 0.0001, **Week 25 vs
Week 9: P = 0.0768; within-group changes sevelamer-HCL: * Week 9 vs
baseline: P = 0.0090, ** Week 25 vs Week 9: P = 0.0242.
3714 A.L.M. de Francisco et al.ated with benefits, such as reduced cardiovascular calci-
fications, reduced hypertension and reduced mortality
[23,24]. Generally, CaMg was well tolerated with an
AE profile consistent with the co-morbidities of a dialysis
patient. AEs definitively related to the study drug were
significantly more frequent in the sevelamer-HCl group
and were gastrointestinal disorders; otherwise, except
for episodes of hypermagnaesemia, no difference was
noted between groups in particular regarding hyper- and
hypocalcaemia, indicating an overall favourable tolerabil-
ity profile of CaMg.
Reflecting the KDIGO CKD-MBD guideline [7], CaMg
offers an alternative phosphate binder option as switching
from pure calcium salts to CaMg may be a possibility re-
stricting the dose of calcium.
In conclusion, CaMg was non-inferior compared with a
well-established non-calcium-containing phosphate binder
at lowering serum phophorus in this controlled, random-
ized, investigator-masked study in 255 patients. There
was a small increase in total serum calcium and no
change in ionized calcium. CaMg led to an asymptomatic
increase in serum magnesium and had a good tolerability
profile.
Supplementary data
Supplementary data is available online at http://ndt.oxford-
journals.org.
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Variations in C-reactive protein during a single haemodialysis session
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Abstract
Background. An increase in C-reactive protein (CRP) le-
vels during a single haemodialysis (HD) session has been
associated with mortality. These associations, however, are
difficult to understand from the current understanding of
CRP metabolism.
Methods. In 190 Swedish haemodialysis (HD) patients
fromtheMappingofInflammatoryMarkersinChronicKid-
ney Disease (MIMICK) cohort, CRP was measured before
and after a HD session. During follow-up, events of death
and censoring were recorded, and hazard ratios were calcu-
lated and analysed as a function of CRP variation. Results
were replicated in 94 Dutch HD patients from the Nether-
lands Cooperative Study on the Adequacy of Dialysis (NE-
COSAD).Inthiscohort,alsocorrelationandkappastatistics
werecalculatedtoassessconcordanceinCRPchangesamid
multiple dialysis sessions from the same individuals.
Results. In both cohorts, mean CRP values did not increase
during a single HD session. In the MIMICK, median (inter-
quartile range) dialysis vintage was 29.0 (14.8–57.0)
months. In both crude [hazard ratio (95% confidence inter-
val): 1.008 (0.971–1.047)] and multivariate Cox models
[0.996 (0.949–1.046)], no association was observed with
mortality. In the NECOSAD, individuals endured 6.0 (6.0–
12.0) months on dialysis. No association was found with
mortality neither in a crude [0.961 (0.908–1.018)] nor in
an adjusted analysis [0.978 (0.923–1.037)].Finally, thecon-
cordance between changes in different sessions was poor.
Conclusions. CRP changes during a single HD session do
not associate with mortality, thereby adding to the biolog-
ical uncertainty concerning the ability of CRP to rise in
such a short period.
Keywords: chronic kidney disease; C-reactive protein; hemodialysis;
inflammatory response; mortality
Introduction
Patients with chronic kidney disease (CKD), and especial-
ly those with end-stage renal disease (ESRD), are at con-
siderable increased risk of premature death [1]. Since the
surplus in CKD mortality is strongly associated with a
state of persistent inflammation and chronic activation of
the acute phase response, the identification of factors in-
volved in the pathogenesis of the inflammatory response
is of considerable therapeutic interest [2–5].
InadditiontoCKD-relatedfactors,suchasdecreasing re-
nal function, co-morbidities, infections or the uraemic envi-
ronment per se [6], the haemodialysis (HD) procedure has
been suggested to play a pivotal role in the development of
inflammation. Indeed,severalstudieshaveshownthat intra-
dialytic activation is associated with increased fractional
synthesis rates of albumin and fibrinogen as well as of
pro-inflammatory cytokines, leading to a state of increased
CRP variations during haemodialysis 3717
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